Johannes Kullmer

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney

Matthias Simon, H.-J. Gröne, Olaf Jöhren et al. · American Journal of Physiology-Renal Physiology · 1995 · 290 citations

Human Renal Ontogenesis, Tumor Biology, Vascular Permeability +17

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Christoph Röllig, Michael Krämer, Christoph Schliemann et al. · Blood · 2020 · 133 citations · Full text

Vascular Endothelial Growth Factor Expression, Vascular Volume, and Capillary Permeability in Human Brain Tumors

Márcia Regina Machein, Johannes Kullmer, Bernd L. Fiebich et al. · Neurosurgery · 1999 · 113 citations

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Christoph Röllig, Hubert Serve, Richard Noppeney et al. · Leukemia · 2021 · 57 citations · Full text